BIOMAT Database Logo BIOMAT Database Logo

Complement activation in thrombotic thrombocytopenic purpura. 2012

M Réti, and P Farkas, and D Csuka, and K Rázsó, and Á Schlammadinger, and M L Udvardy, and K Madách, and G Domján, and C Bereczki, and G S Reusz, and A J Szabó, and Z Prohászka
Department of Hematology and Stem Cell Transplantation, St István and St László Hospital of Budapest, Budapest, Hungary.

BACKGROUND Ultra-large von Willebrand factor and deficiency of its cleaving protease are important factors in the events leading to thrombotic microangiopathy; however, the mechanisms involved are only partly understood. Whereas pathological activation of the alternative complement pathway is linked to atypical hemolytic uremic syndrome, the role of complement activation in thrombotic thrombocytopenic purpura (TTP) is unknown. The aim of this study was to investigate whether signs of complement activation are characteristic of TTP. METHODS Twenty-three patients with TTP (18 women, median age 38 years) and 17 healthy controls (13 women, median age 38 years) were included. Complement parameters (C3, Factors H, I, B and total alternative pathway activity) together with complement activation fragments (C3a) or complexes (C1rs-INH, C3bBbP, sC5b9) were measured by ELISA or RID. ADAMTS13 activity and anti-ADAMTS13 inhibitory antibodies were measured by the VWF-FRET73 assay. RESULTS Increased levels of C3a, and SC5b9 were observed in TTP during acute episodes, as compared with healthy controls. Decreased complement C3 levels indicative of complement consumption occurred in 15% of acute TTP patients. Significant decrease of complement activation products C3a and SC5b9 was observed during plasma exchange (PEX). The sustained presence of anti-ADAMTS13 inhibitory antibodies in complete remission was associated with increased complement activation. CONCLUSIONS These data document in an observational study the presence of complement activation in TTP. Further investigation is needed to determine its potential pathogenetic significance.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010951 Plasma Exchange Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions. Exchange, Plasma,Exchanges, Plasma,Plasma Exchanges
D011697 Purpura, Thrombotic Thrombocytopenic An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases. Moschkowitz Disease,Purpura, Thrombotic Thrombopenic,Thrombotic Thrombocytopenic Purpura, Congenital,Thrombotic Thrombocytopenic Purpura, Familial,Congenital Thrombotic Thrombocytopenic Purpura,Familial Thrombotic Thrombocytopenia Purpura,Familial Thrombotic Thrombocytopenic Purpura,Microangiopathic Hemolytic Anemia, Congenital,Moschcowitz Disease,Schulman-Upshaw Syndrome,Thrombotic Microangiopathy, Familial,Thrombotic Thrombocytopenic Purpura,Upshaw Factor, Deficiency of,Upshaw-Schulman Syndrome,Familial Thrombotic Microangiopathy,Microangiopathy, Familial Thrombotic,Schulman Upshaw Syndrome,Thrombocytopenic Purpura, Thrombotic,Thrombopenic Purpura, Thrombotic,Thrombotic Thrombopenic Purpura,Upshaw Schulman Syndrome
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Réti, and P Farkas, and D Csuka, and K Rázsó, and Á Schlammadinger, and M L Udvardy, and K Madách, and G Domján, and C Bereczki, and G S Reusz, and A J Szabó, and Z Prohászka
Complement in thrombotic thrombocytopenic purpura.
December 1983, American journal of hematology,
M Réti, and P Farkas, and D Csuka, and K Rázsó, and Á Schlammadinger, and M L Udvardy, and K Madách, and G Domján, and C Bereczki, and G S Reusz, and A J Szabó, and Z Prohászka
Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura.
May 2023, Blood,
M Réti, and P Farkas, and D Csuka, and K Rázsó, and Á Schlammadinger, and M L Udvardy, and K Madách, and G Domján, and C Bereczki, and G S Reusz, and A J Szabó, and Z Prohászka
Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura.
October 2013, Journal of thrombosis and haemostasis : JTH,
M Réti, and P Farkas, and D Csuka, and K Rázsó, and Á Schlammadinger, and M L Udvardy, and K Madách, and G Domján, and C Bereczki, and G S Reusz, and A J Szabó, and Z Prohászka
Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura.
March 2014, British journal of haematology,
M Réti, and P Farkas, and D Csuka, and K Rázsó, and Á Schlammadinger, and M L Udvardy, and K Madách, and G Domján, and C Bereczki, and G S Reusz, and A J Szabó, and Z Prohászka
Platelet activation in patients with thrombotic thrombocytopenic purpura.
February 1993, American journal of hematology,
M Réti, and P Farkas, and D Csuka, and K Rázsó, and Á Schlammadinger, and M L Udvardy, and K Madách, and G Domján, and C Bereczki, and G S Reusz, and A J Szabó, and Z Prohászka
[Thrombocytopenic thrombotic purpura after immune thrombocytopenic purpura].
December 1993, Sangre,
M Réti, and P Farkas, and D Csuka, and K Rázsó, and Á Schlammadinger, and M L Udvardy, and K Madách, and G Domján, and C Bereczki, and G S Reusz, and A J Szabó, and Z Prohászka
Thrombotic thrombocytopenic purpura.
May 1952, Acta medica Scandinavica,
M Réti, and P Farkas, and D Csuka, and K Rázsó, and Á Schlammadinger, and M L Udvardy, and K Madách, and G Domján, and C Bereczki, and G S Reusz, and A J Szabó, and Z Prohászka
Thrombotic thrombocytopenic purpura.
February 1992, The Journal of the Association of Physicians of India,
M Réti, and P Farkas, and D Csuka, and K Rázsó, and Á Schlammadinger, and M L Udvardy, and K Madách, and G Domján, and C Bereczki, and G S Reusz, and A J Szabó, and Z Prohászka
Thrombotic thrombocytopenic purpura.
August 1975, Obstetrics and gynecology,
M Réti, and P Farkas, and D Csuka, and K Rázsó, and Á Schlammadinger, and M L Udvardy, and K Madách, and G Domján, and C Bereczki, and G S Reusz, and A J Szabó, and Z Prohászka
Thrombotic thrombocytopenic purpura.
March 2004, Indian pediatrics,
Copied contents to your clipboard!